Algernon Pharmaceuticals Inc (AGNPF)

[Money $hot]

TCM55

We know that the company's Ifenprodil focus had modified and that the company"s efforts were mainly COVID in 2020-2021. They got it done under adverse issues. A Phase 3 was not pursued due to costs and vaccinations. The company PR'ed the strong ILK-6 data and obviously has that Trial's data as support for future applications.

IPF/CC was delayed due to COVID but many here hope that Data may finally substantiate Ifenprodil's value for these Lung diseases and to support other Trial applications.

2021 brought licensing of Sub-hallucinogenic micro dose DMT research to pursue along with world class advisors. UK-MHRA applications in 2-2022.

AGN also found and licensed the Stroke research from Dr North (Topotecan) about the SCLC/Pancreatic tumor stuff. Very encouraging, IMO. (personal interest in cancer)

Not bad for a speculative investment, IMO. Buy -Hold - Sell...

I hope you're right about the FDA and implied UK-MHRA approvals of Clinical Trials. I've seen one with DMT and smoking.?.
BUTT... Of course it's not that easy. JMHFO...GLTA...

1. I'm unaware of what company you are referring to as it relates to having "got it done under adverse issues." What I believe is those adverse issues you are talking about are inherent/predictable within the basement bargain bin framework that we now see is Algernon's business model. Those adverse issues are happening because of running studies in countries where management has absolutely no control over the process. Everything is outsourced halfway around the world and zero accountability. Thus, Moreau continues to point the finger at this that and the third about it all being something or someone else's fault. I'm not falling for it hook line and sinker. Also, I have no idea what company you are talking about as it relates to a continued pursuit of a Phase 3 clinical trial for COVID-19. Dude, hear this loud and clear...THERE WAS ABSOLUTELY ZERO...I REPEAT... ZERO STATISTICAL SIGNIFICANCE to make any sane move towards running a Phase 3 clinical trial for COVID-19. It would have been pure madness! Like, did you actually read Andre Uddin's analysis back in 2021 about the flopped Topline data? If not, I suggest you read it to gain glaring clarity.

2. Once again, the reason why you still don't have data from IPF/CC is because Moreau stuck a silly little 20 person study halfway around the world in a market he knew in advance had problems with recruitment. That is separate from the COVID-19 further compounding the problem. COVID is after the fact and it simply magnified how shitty a deal they made in Australia from the start. One can try to revise history but fortunately many of us were there to see the nightmare unfold with our own two eyes. I'm not here to offer anyone a watered down and/or watery eyed version of the story.

3. DMT is the flavor of the month that's going stale with delays one quarter after the next. Starting with a supposed launch back in Q2 2021. What's it now...Q2 2022 and fast approaching Q3. Algernon continues it's dismal record of executing anything in their pipeline on their intended timeline.

Great, DMT for brain surgery. Could it get anymore complicated?

Great, Pancreatic Cancer. Could it get anymore complicated?

4. "I hope you're right about the FDA and implied UK-MHRA approvals of Clinical Trials." - TCM55

I have no idea who you are talking about regarding being right? Right about what...about the FDA?

I have no posts here going on and on about UK-MHRA. That's been your focus here for who knows how long now.

5. Algernon Pharmaceuticals business model is a slow moving train wreck after Speed Demon Moreau drive the bus over the cliff. Algernon has a newly revised business model where now they will spend lord knows how long at Phase 1. Couple Phase 1 to Algernon's Phase 2 pilot studies to determine IF they will then run a Phase 2 study powered for statistical significance. What that means is Algernon's business model is designed to be at Phase 2 for FIVE to SIX years before ever possibly getting to Phase 3. Simply look at the IPF/CC study for real world proof. After the pending data readout, management will then determine IF they will run a STAT SIG Phase 2 clinical trial...and that clinical trial will also be conducted in Australia at a snails pace due to a small recruitment pool of participants. Sir, Algernon Pharmaceuticals is a dilution machine cloaked in the appearance of being a serious biotech company. Algernon will be lucky to get to a Phase 2 STAT SIG data readout within the next 3 years for IPF and/or Chronic Cough. In regards to the DMT and Cancer studies... Algernon will not get to a Phase 2 STAT SIG data readout for at least another 6 or 7 years - if ever.

"Everybody wants in at Phase 2" - Christopher J. Moreau, CEO @ Algernon Pharmaceuticals Inc.

Did Moreau forget to tell you that even if ^that were true (which it's not), would that be Phase 2 pilot studies or Phase 2 STAT SIG studies? It's a BIG DIFFERENCE (like night and day) and Moreau knows it!
____________________

6th Sense Sarcasm:

Did I mention, all the DELAYS and inherent DILUTION tactics will DRAG on throughout a global recession, escalating wars, the ongoing pandemic (pick a disease), Cannabix Technologies finally going belly up, the world's first Trillionaire on paper, the end of American democracy as we know it, and landing the first Man On Mars.

https://algernonpharma.com/

Have @ it

M$